Information for continuing education (CE) credit

**Spring 2021 Chief Medical Officer Network Meeting Series – Joint Session**

Activity date: April 08, 2021

Course director: Will Dardani, MBA

Vizient is committed to complying with the criteria set forth by the accrediting agencies in order to provide this quality course. To receive credit for educational activities, you must successfully complete all course requirements.

**Requirements**

1. Attend the course in its entirety
2. After the course, you will receive an email with instructions and an access code that you will need to obtain your CE credit
3. **Complete the process no later than May 23, 2021**

Upon successful completion of the course requirements, you will be able to print your CE certificate.

**Learning objectives**

1. Assess the likelihood of potential disruptiveness to healthcare as a result of the experience of the COVID-19 pandemic.
2. Identify two categories in healthcare where big changes may occur as a result of the COVID-19 experience.
3. Examine organizational preparedness across several domains.



**Joint Accreditation Statement:**

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

**Designation Statements:**

### PHYSICIAN

Vizient, Inc. designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s) ™.*Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CEU

Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

**CONFLICT OF INTEREST/CONTENT VALIDATION POLICY:**

As an accredited provider of continuing medical education/continuing education Vizient is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. Vizient requires all potential faculty and program planners, in advance, to disclose financial relationships with relevant commercial interests. Vizient uses that information to determine whether prospective contributors have potential conflicts of interest. If significant relationships are disclosed, Vizient assesses how those potential conflicts of interest may affect CME/CE content. Vizient requires that all conflicts of interest be resolved prior to participation in the activity. Vizient is committed to resolving potential conflicts of interest, although if contributors have significant relationships that cannot be reconciled, Vizient reserves the right to prohibit participation. Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

### DISCLOSURE STATEMENTS:

### Current accrediting agency guidelines and Vizient policy state that participants in educational activities should be made aware of any affiliation or financial interest that may affect the presentation and if there will be any discussion of unapproved or investigative use of commercial products/devices. Each planning committee member, reviewer and presenter has completed a Disclosure of Relevant Financial Relationships form.

Relevant financial relationships: Planning committee members and presenters have nothing to disclose

### Planning committee members

Tom Villanueva, DO, MBA, FACPE, SFHM

Associate Vice President, Clinical Resources (PHYSICIAN PLANNER)

Vizient, Inc

Will Dardani, MBA

Networks Senior Director

Vizient

Donna McNutt, MS, RN

Networks Director (NURSE PLANNER)

Vizient, Inc.

Jacob Seal, MS

Networks Manger

Vizient, Inc

### Presenters

Tom Robertson, MBA

Executive Director, Vizient Research Institute

Vizient, Inc.